Methylphenidate in children with ADHD with or without learning disability.

To explore treatment response to Osmotic Release Oral System(®) (OROS) methylphenidate in children with ADHD with and without comorbid learning disability (LD).
Data were analyzed from two 6-week, double-blind, randomized, placebo-controlled, crossover studies evaluating individually determined doses of OROS methylphenidate versus placebo in 135 children (ages 9 to 12 years) with ADHD with or without an LD in reading, math, or both. The sample was demographically diverse, with 31% females and more than 40% minority, predominantly African American and Hispanic. On two laboratory school days, participants received either OROS methylphenidate or placebo and were given a battery of cognitive and behavioral tests.
Treatment with OROS methylphenidate led to improvement in ADHD Rating Scale scores for participants with or without comorbid LD. Both groups performed better during treatment with OROS methylphenidate than placebo on measures of cognitive skills (i.e., Test of Variables of Attention, Finger Windows Backwards), academically related tasks (i.e., Dynamic Indicators of Basic Early Literacy Skills, Test of Handwriting Skills-Revised, Permanent Product Math Test), and observed classroom behavior (i.e., Swanson, Kotkin, Alger, M-Flynn, and Pelham Scale).
In children with ADHD with or without comorbid LD, behavior and performance improved during treatment with OROS methylphenidate.
AuthorsDavid Williamson, Desiree W Murray, C V Damaraju, Steve Ascher, H Lynn Starr
JournalJournal of attention disorders (J Atten Disord) Vol. 18 Issue 2 Pg. 95-104 (Feb 2014) ISSN: 1557-1246 [Electronic] United States
PMID22628142 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Central Nervous System Stimulants
  • Methylphenidate
  • Administration, Oral
  • Attention (drug effects)
  • Attention Deficit Disorder with Hyperactivity (diagnosis, drug therapy, epidemiology)
  • Central Nervous System Stimulants (administration & dosage, therapeutic use)
  • Child
  • Cognition (drug effects)
  • Comorbidity
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Humans
  • Learning Disorders (epidemiology)
  • Male
  • Methylphenidate (administration & dosage, therapeutic use)
  • Psychiatric Status Rating Scales
  • Schools
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: